ArticleSurgical case reports2025
Successful Management of Esophageal Sarcomatoid Carcinoma with Neoadjuvant Chemotherapy and Esophagectomy.
Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEsophageal sarcomatoid carcinoma (ESC) is a rare malignancy characterized by both carcinomatous and sarcomatous components, with no established perioperative chemotherapy standards. CASE PRESENTATION: We report a case of advanced ESC (T3N1M0, Stage III) treated with 2 courses of neoadjuvant docetaxel, cisplatin, and fluorouracil (DCF) chemotherapy, followed by robotic-assisted thoracoscopic esophagectomy. Histopathology revealed the complete disappearance of spindle cell components, although residual squamous cell carcinoma was found in the flat mucosa. The patient remained recurrence-free for 26 months postoperatively without adjuvant therapy.
conclusionsThis case suggests that preoperative DCF chemotherapy may be effective for ESC, especially when combined with complete surgical resection, highlighting the importance of addressing both the sarcomatoid and squamous components for long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.